Last reviewed · How we verify
AB-106, digoxin
Digoxin inhibits the sodium-potassium ATPase pump.
Digoxin inhibits the sodium-potassium ATPase pump. Used for Atrial fibrillation, Heart failure.
At a glance
| Generic name | AB-106, digoxin |
|---|---|
| Sponsor | Nuvation Bio Inc. |
| Drug class | Cardiac glycoside |
| Target | Sodium-potassium ATPase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
Digoxin works by inhibiting the sodium-potassium ATPase pump, which leads to an increase in intracellular sodium and a decrease in intracellular potassium. This increase in intracellular sodium and decrease in intracellular potassium increases the force of cardiac contractions and slows the heart rate.
Approved indications
- Atrial fibrillation
- Heart failure
Common side effects
- Nausea
- Vomiting
- Arrhythmia
- Dysrhythmia
- Bradycardia
- Hypotension
- Fatigue
- Headache
- Dizziness
- Confusion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB-106, digoxin CI brief — competitive landscape report
- AB-106, digoxin updates RSS · CI watch RSS
- Nuvation Bio Inc. portfolio CI